2008
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
Brimo F, Vollmer R, Corcos J, Kotar K, Bégin L, Humphrey P, Bismar T. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008, 53: 177-183. PMID: 18752501, DOI: 10.1111/j.1365-2559.2008.03087.x.Peer-Reviewed Original ResearchConceptsPathological stageTumor lengthPrognostic valueTumor extentFinal pathological stageHigher stage diseaseNeedle biopsy specimenCancer patient outcomesPrognostic significanceBiochemical recurrenceBiopsy specimenRadical prostatectomyPatient outcomesBiopsy reportingFailure statusCancer lengthPositive coresPathological outcomesLarger studyMorphometric measurementsDiscontinuous fociCancerCore tissuePatientsOutcomes
2004
Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480
Humphrey P, Halabi S, Picus J, Vogelzang N, Small E, Kantoff P. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. Journal Of Clinical Oncology 2004, 22: 9613-9613. DOI: 10.1200/jco.2004.22.14_suppl.9613.Peer-Reviewed Original ResearchScatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480
Humphrey P, Halabi S, Picus J, Vogelzang N, Small E, Kantoff P. Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. Journal Of Clinical Oncology 2004, 22: 9613-9613. DOI: 10.1200/jco.2004.22.90140.9613.Peer-Reviewed Original Research
2001
The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer
Vollmer R, Humphrey P. The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer. American Journal Of Clinical Pathology 2001, 116: 864-870. PMID: 11764075, DOI: 10.1309/7mq7-mwar-4w8a-r75f.Peer-Reviewed Original ResearchConceptsElevated PSA levelsEarly deathPSA levelsRadical prostatectomyProstate cancerPathology observationsGleason grade 5Overall good prognosisTime of prostatectomyPostoperative levelsPSA failureStudy patientsBetter prognosisProgressive tumorsPrognostic categoriesPercentage carcinomaProstatectomySubsequent outcomesLower hazardDeathSurgeryHigher hazardCancerMenPSAFrequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma
Abdulkadir S, Carbone J, Naughton C, Humphrey P, Catalona W, Milbrandt J. Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Human Pathology 2001, 32: 935-939. PMID: 11567222, DOI: 10.1053/hupa.2001.27102.Peer-Reviewed Original ResearchConceptsHuman prostate cancerHuman prostate carcinomaProstate cancerProstate carcinomaProstatic intraepithelial neoplasia lesionsIntraepithelial neoplasia lesionsProstate carcinoma specimensExpression of Nab2Prostate tumor suppressorNeoplasia lesionsTumor gradeCarcinoma specimensProstate tumorigenesisTumor progressionTranscription factor EGR1Protein expressionEarly lossEGR1 levelsCarcinomaTumorigenic processCancerTumor suppressorSame stimuliEGR1Transcriptional activityImpaired prostate tumorigenesis in Egr1-deficient mice
Abdulkadir S, Qu Z, Garabedian E, Song S, Peters T, Svaren J, Carbone J, Naughton C, Catalona W, Ackerman J, Gordon J, Humphrey P, Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nature Medicine 2001, 7: 101-107. PMID: 11135623, DOI: 10.1038/83231.Peer-Reviewed Original ResearchConceptsEarly growth response protein 1Prostate cancerTumor progressionProstatic intra-epithelial neoplasiaEgr1 deficiencyIntra-epithelial neoplasiaHigh-resolution magnetic resonance imagingTransgenic mouse modelHuman prostate cancerTumor growth rateEgr1-deficient miceMagnetic resonance imagingProstate tumor progressionMouse modelProstate tumorigenesisSurvival analysisResonance imagingCarcinomaTumor developmentProtein 1ProgressionCancerMiceDeficiencyEGR1
1998
A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
Garabedian E, Humphrey P, Gordon J. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 15382-15387. PMID: 9860977, PMCID: PMC28051, DOI: 10.1073/pnas.95.26.15382.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstatic intraepithelial neoplasiaTransgenic mouse modelProstate cancerIntraepithelial neoplasiaMouse modelNeuroendocrine cellsHuman prostate cancerNeuroendocrine cell lineagesWeeks of ageNeuroendocrine differentiationSimian virus 40 T antigenLocal invasionMouse prostateCancerNeoplasiaProstateWeeksT antigenCell lineagesTransgene expressionMultiple pedigreesCellsMetastasisAndrogensPercentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population
Arcangeli C, Humphrey P, Smith D, Harmon T, Shepherd D, Keetch D, Catalona W. Percentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population. Journal Of Urology 1998, 160: 1580-1581. DOI: 10.1016/s0022-5347(01)62623-5.Peer-Reviewed Original ResearchPercentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population
Arcangeli C, Humphrey P, Smith D, Harmon T, Shepherd D, Keetch D, Catalona W. Percentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population. Journal Of Urology 1998, 160: 1580-1581.. DOI: 10.1097/00005392-199810000-00125.Peer-Reviewed Original ResearchPercentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population fn1fn1This study was supported in part by a grant from Hybritech Incorporated, San Diego, California.
Arcangeli C, Humphrey P, Smith D, Harmon T, Shepherd D, Keetch D, Catalona W. Percentage of Free Serum Prostate-Specific Antigen as a Predictor of Pathologic Features of Prostate Cancer in a Screening Population fn1fn1This study was supported in part by a grant from Hybritech Incorporated, San Diego, California. Urology 1998, 51: 558-565. PMID: 9586607, DOI: 10.1016/s0090-4295(98)00035-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate cancerPathologic featuresFree serum prostate-specific antigenSerum prostate-specific antigenFree prostate-specific antigenCancerous surgical marginsProstate cancer screeningPercentage of cancerRadical prostatectomy specimenHarmless cancersPreoperative predictorsWatchful waitingSurgical marginsCapsular penetrationProstatic capsuleGleason scoreCancer screeningRadical prostatectomyProstatectomy specimenTumor volumeFPSAClinical practiceCancerScreening evaluation
1996
Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy.
Shepherd D, Keetch D, Humphrey P, Smith D, Stahl D. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. Journal Of Urology 1996, 156: 460-2; discussion 462-3. PMID: 8683703, DOI: 10.1097/00005392-199608000-00038.Peer-Reviewed Original ResearchConceptsHigh-grade prostatic intraepithelial neoplasiaGrade prostatic intraepithelial neoplasiaProstatic intraepithelial neoplasiaIntraepithelial neoplasiaRepeat biopsyNeedle biopsyBiopsy techniqueSide of cancerProstate needle biopsyLocation of cancerInitial biopsySystematic biopsyMen 31Biopsy strategyBiopsyNeoplasiaCancerProstateQuadrant locationStrongest predictorPatientsMenSame sideMalignancyDiseaseRepeat Biopsy Strategy in Men with Isolated Prostatic Intraepithelial Neoplasia on Prostate Needle Biopsy
Shepherd D, Keetch D, Humphrey P, Smith D, Stahl D. Repeat Biopsy Strategy in Men with Isolated Prostatic Intraepithelial Neoplasia on Prostate Needle Biopsy. Journal Of Urology 1996, 156: 460-463. DOI: 10.1016/s0022-5347(01)65881-6.Peer-Reviewed Original ResearchConceptsHigh-grade prostatic intraepithelial neoplasiaGrade prostatic intraepithelial neoplasiaProstatic intraepithelial neoplasiaIntraepithelial neoplasiaRepeat biopsyNeedle biopsyBiopsy techniqueSide of cancerProstate needle biopsyLocation of cancerPercent of casesInitial biopsySystematic biopsyMen 31Biopsy strategyBiopsyNeoplasiaCancerProstateQuadrant locationPatientsStrongest predictorMenSame sideMalignancyClinical and Pathological Features of Hereditary Prostate Cancer
Keetch D, Humphrey P, Smith D, Stahl D, Catalona W. Clinical and Pathological Features of Hereditary Prostate Cancer. Journal Of Urology 1996, 155: 1841-1842.. DOI: 10.1097/00005392-199606000-00004.Peer-Reviewed Original ResearchHereditary prostate cancerSporadic prostate cancerProstate cancerPathological featuresGleason scoreSerum prostate-specific antigen (PSA) concentrationProstate-specific antigen concentrationDate of surgeryMean Gleason scoreSpecific antigen concentrationLow Gleason scoreHereditary diseaseRadical prostatectomy specimensFamily historyPathological differencesAbstract PurposeProstatectomy specimensMedian percentageSporadic carcinomasCancerAntigen concentrationSporadic cancersCarcinomaMenDiseaseClinical and Pathological Features of Hereditary Prostate Cancer
Keetch D, Humphrey P, Smith D, Stahl D, Catalona W. Clinical and Pathological Features of Hereditary Prostate Cancer. Journal Of Urology 1996, 155: 1841-1843. PMID: 8618269, DOI: 10.1016/s0022-5347(01)66024-5.Peer-Reviewed Original ResearchConceptsHereditary prostate cancerSporadic prostate cancerProstate cancerPathological featuresGleason scoreSerum prostate-specific antigen (PSA) concentrationProstate-specific antigen concentrationDate of surgeryMean Gleason scoreSpecific antigen concentrationLow Gleason scoreHereditary diseaseRadical prostatectomy specimensFamily historyPathological differencesProstatectomy specimensMedian percentageSporadic carcinomasCancerAntigen concentrationSporadic cancersCarcinomaMenDiseaseScores
1995
Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia
Epstein J, Grignon D, Humphrey P, McNeal J, Sesterhenn I, Troncoso P, Wheeler T. Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia. The American Journal Of Surgical Pathology 1995, 19: 873-886. PMID: 7611534, DOI: 10.1097/00000478-199508000-00002.Peer-Reviewed Original ResearchConceptsHigh-grade PINLow-grade PINInterobserver reproducibilityProstatic intraepithelial neoplasiaSmall atypical glandsBenign prostate tissueIntraepithelial neoplasiaSame histologyAtypical glandsBiopsy materialProminent nucleoliUniform diagnosisCribriform glandsProstate tissueCancerLesionsLevel of agreementDiagnostic issuesUniform agreementPathologistsGlandDiagnosisConsecutive examplesBiopsyGroup
1992
Immunoreactive Prostatic Specific Antigen in Male Periurethral Glands
Frazier H, Humphrey P, Burchette J, Paulson D. Immunoreactive Prostatic Specific Antigen in Male Periurethral Glands. Journal Of Urology 1992, 147: 246-248. PMID: 1370330, DOI: 10.1016/s0022-5347(17)37206-3.Peer-Reviewed Original ResearchConceptsProstatic specific antigenProstatic acid phosphatasePeriurethral glandsSpecific antigenUrethral specimensMalignant prostatic tissueMale urethral specimensAutopsy seriesUrethral biopsyProstatic cancerAntigen uniqueAutopsy specimensProstatic tissueStrong immunostainingHeterogenous stainingAntigenAcid phosphataseRecent evidenceGlandTissueBiopsyEvidencePatientsCancerImmunostaining
1988
The ratio of prostate chips with cancer:A new measure of tumor extent and its relationship to grade and prognosis
Humphrey P, Vollmer R. The ratio of prostate chips with cancer:A new measure of tumor extent and its relationship to grade and prognosis. Human Pathology 1988, 19: 411-418. PMID: 3366451, DOI: 10.1016/s0046-8177(88)80490-8.Peer-Reviewed Original ResearchConceptsProstate cancerAdditive prognostic informationStage of tumorGleason histologic scoreChoice of patientsChance of deathCurative surgeryExtensive diseaseLocalized diseaseTransurethral prostatectomyGleason scoreProstate chipsPrognostic informationTumor extentHistologic scoresPatientsCancerLong-term failureDiseaseReliable predictorScoresInitial studyTotal numberPrognosticatorProstatectomy